At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the ...

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

ART post-RC in MIBC patients shows no significant increase in acute or late toxicity, with mild bowel toxicity being more frequent. Historical concerns about bowel exposure have limited ART use, but ...

Tang discusses the limitations in available data, but nonetheless high potential, of SBRT in kidney cancer. As Tang noted in his ASTRO 2024 presentation topic, SBRT has been linked to significantly ...

Oliver Sartor, MD, discusses how 68galliumPSMA-11 PET-CT imaging is utilized in prostate cancer management, addressing its clinical applications, availability challenges, role in treatment eligibility ...

At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide. The panel examines the significance of ...